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Abstract
AIM: Ribavirin (RBV) shows a strong antiviral effect on
hepatitis C virus when used in combination with interferon.
However, RBV-induced anemia is a major problem in this
therapy. It would be of great clinical importance to
ameliorate the anemia without reducing the RBV dose.
We report here that, Ninjinyoeito (NYT), a herbal medicine
can reduce the RBV-induced anemia.
METHODS: Twenty-three patients with chronic hepatitis
C were treated with interferon alpha 2b plus RBV with
(NYT group) or without (control group) NYT by a randomized
selection. Eighteen patients completed the treatment
schedule, and hemato-biochemical and virological effects
were evaluated.
RESULTS: There was no significant difference in
biochemical and virological responses between the two
groups. However, anemia was significantly reduced in
the NYT group compared with the control group. The
maximal decrease of Hb in the NYT group (2.59±1.10 g/dL)
was significantly (P = 0.026) smaller than that in the control
group (3.71±0.97 g/dL). There was no significant difference
in serum glutathione peroxidase activity, serum RBV
concentration, and Th1/Th2 balance between the two
groups. There was no specific adverse effect in NYT
administration.
CONCLUSION: These results suggest that NYT could be
used as a supportive remedy to reduce the RBV-induced
anemia in the treatment of chronic hepatitis C.
© 2005 The WJG Press and Elsevier Inc. All rights reserved.
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INTRODUCTION
Chronic hepatitis C often gradually progresses to cirrhosis,
and hepatocellular carcinoma develops especially in advanced
hepatic fibrosis[1]. Recently, ribavirin (RBV) has been used
in combination with pegylated interferon (IFN) as the most
effective antiviral therapy[2]. However, RBV-induced anemia
is the major dose-limiting factor in the combined therapy
of  RBV and IFN products[3]. The pathogenesis of  RBV-
induced anemia is reported to be the destruction of
erythrocytes due to the retention of RBV inside the
erythrocytes because there is no RBV dephosphorylase in
erythrocytes[4], possibly leading to the oxidative damage to
the erythrocytic membrane. When anemia is progressive,
the dose of RBV is usually reduced, and even the IFN-RBV
therapy itself might be stopped in case of severe anemia.
If  we could prevent or at least reduce RBV-induced anemia
to some extent, patients would receive a sufficient amount
of RBV and could show a favorable virological response.
There have been only a few reports on the attempt to
ameliorate the RBV-induced anemia[5,6].
Ninjinyoeito (NYT), a herbal medicinal formula, shows
antiviral action on hepatitis C virus (HCV)[7], as well as
antioxidant[8], immunomodulatory[9], and hematopoietic[10-12]
effects. We speculated that the antioxidant effect of  NYT
could protect the erythrocytic membrane from the RBV-induced
hemolysis and that NYT would promote erythropoiesis in
response to the RBV-induced anemia.
In this report, we aimed to elucidate a beneficial effect




Patients with chronic hepatitis C were selected for the
treatment protocol with the following criteria: serum levels
of  HCV-RNA more than 100 kIU/mL by RT-PCR (or
more than 1 Meq/mL by a branched DNA probe assay) in
naive patients, or ineffective or recurrent after the interferon
monotherapy. Patients were excluded due to the following
criteria: pregnant women, allergic to interferon, administration
of a herbal medicine “Shosaikoto”, severe heart failure,
chronic renal failure, and past history of  depression. Twenty-
4014           ISSN 1007-9327     CN 14-1219/ R     World J Gastroenterol     July 14, 2005   Volume 11   Number 26
three patients with chronic hepatitis C were enrolled into
this study. Seventeen were male and six were female. The
mean age of the patients was 51.1 (range 26-74). The diagnosis
was confirmed histologically with liver biopsy in 13 patients.
The other patients were diagnosed by hematological,
biochemical, and virological findings.
Treatment protocol
Interferon-alpha 2b (Intron A®, Schering-Plough, Kenilworth,
NJ, USA) and RBV (Rebetol®, Schering-Plough) were used
as antiviral agents as previously described[6,7]. In principle,
interferon-alpha 2b (IFN) was administered intramuscularly
6 d a week for 2 wk at a dose of 10 MU, then thrice a week
for 22 wk at the same dose. RBV was administered orally
for 24 wk at a dose of 800 mg per day when the patient
had a body weight over 60 kg, and at a dose of 600 mg
when under 60 kg. Ninjinyoeito extract granules (NYT,
Chinese name: Renshen-yangrong-tang, TJ-108, Tsumura
& Co., Tokyo, Japan), including 6.0 g of  NYT extract, was
administered orally for 24 wk at a dose of 9 g per day. The
patients were assigned into two groups in a random selection
(Figure 1). The NYT group was treated with the three agents
(IFN, RBV, and NYT), and the control group was treated
with the two agents (IFN and RBV). No specific drugs were
administered after the 24-wk treatment. A written informed
consent was obtained from all the patients enrolled. Criteria
for dose-down or stopping of the IFN and RBV were as
follows: criteria by hemoglobin (Hb): dose-down of RBV
from 800 to 600 mg or from 600 to 400 mg/d without the
change of IFN dose when Hb less than 10 g/dL; administration
of both IFN and RBV were stopped when Hb less than
8.5 g/dL; criteria by WBC and platelet counts: dose down
of IFN without the change of RBV dose when WBC counts
were less than 1 500/µL or platelet counts were 50 000/µL;
administration of both IFN and RBV were stopped when
WBC counts were less than 1 000/µL or platelet counts
were 25 000/µL. Other criteria for dose-down or
discontinuation of treatment included subjective symptoms
such as anorexia, general malaise, or depressive tendency.
Figure 1  Study design.
Blood sampling and laboratory tests
Approximately 20 mL of blood was taken from the patients
before treatment and again at 2, 4, 8, 12, and 24 wk after
the start of treatment, and 24 wk after the end of treatment.
Hematological, biochemical, and virological tests were
performed.
HCV-RNA assay and HCV serotypes
Serum HCV-RNA was detected with an Amplicor HCV
test (Roche Diagnostics, Tokyo, Japan), and was quantified
using an Amplicor HCV Monitor test, version 2.0, Roche
Diagnostics). Serotypes of  HCV were determined using an
enzyme immunoassay (Genotyping EIA, International
Reagents, Kobe, Japan). Sustained virological response (SVR)
was considered to be obtained when the serum HCV-RNA
was negative and serum ALT was within normal limits at
24 wk from the end of the IFN/RBV treatment.
Determination of ribavirin concentration
RBV concentration was determined in 18 patients, using
high performance liquid chromatography (HPLC, SRL,
Tokyo, Japan). Two-hundred microliters of  serum was
applied to HPLC after deproteination. The range of this
assay system was from 50 to 20 000 ng/mL.
Determination of serum erythropoietin concentration
Serum levels of erythropoietin concentration were
determined in eight male patients at wk 0 and 4 (four patients
from each group), using radioimmunoassay (SRL, Inc.,
Tokyo, Japan). The eight patients were selected because
their sera were available and it was considered to be adequate
to compare the male patients only instead of mixing a few
female patients.
Measurement of Th1/Th2 balance
The Th1/Th2 balance as a marker for cellular immunological
response was assayed using the flow cytometry-based
“Fastimmune Cytokine System” (Beckton Dickinson
Biosciences, San Jose, CA, USA). Briefly, the blood was
collected in sodium heparin, and was activated with
ionomycin (IM), Brefeldin-A (BFA), and phorbol 12-
myristate 13 acetate (PMA). After lysing and permeabilization,
intracellular staining with fluorescent-conjugated monoclonal
antibodies against cytokines was done. The two-color
interferon-γ/interleukin-4 staining (Fastimmune system,
Beckton Dickinson Biosciences) was utilized. Laser flow
cytometer (FACS Caliber, Beckton Dickinson Biosciences)
was used for analysis.
Glutathione peroxidase assay
Glutathione peroxidase activity as an antioxidant activity
was determined using the Glutathione Peroxidase Assay kit
(Cayman Chemical Company, Ann Arbor, MI, USA).
Statistical analysis
The software package Statmate III (Atms, Tokyo, Japan)
was used for statistical analysis. The two-tailed Mann-Whiney
U test was used to assess the significance of difference
between the various laboratory test items such as Hb. The
Fisher’s exact test was used for the comparison of antiviral
effects between the two groups. Multiple regression analysis
was performed for the analysis on the factors influencing
the anemia. All data were expressed as the mean±SD. A P
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RESULTS
Enrollment and follow-up of the registered patients
Patients were treated with IFN plus RBV either with (n = 13)
or without (n = 10) NYT. Eighteen patients (nine patients
in each group) completed the 24-wk treatment. There were
five patients who dropped out due to anorexia and general
malaise in three cases (all in the control group) and due to
social problems in two cases (one case in each group). There
was no significant difference between the NYT and control
groups in age, gender, body weight, serum ALT levels, Hb
levels, HCV-RNA levels before treatment, and HCV
serotypes (Table 1). During the course of  treatment, the
dose of RBV was stopped in 1 patient, but not reduced in
any of the remaining 9 patients in the NYT group, whereas it
was reduced due to anemia in 2 of 13 patients, resulting in
stopping of RBV in 4 patients in the control group (P = 0.45).
Table 1  Patients’ characteristics before therapy
        NYT             Control              P
Age (yr)   46.3±14.3           54.9±10.3             0.113
Gender (M/F)          9/1                  8/5             0.123
Body weight (kg)   65.2±9.8           60.6±9.1             0.291
ALT (U/L)   74.9±38.2           58.1±25.1             0.457
Hb ( g/dL)   14.3±1.4           14.0±1.6             0.709
HCVRNA (kIU/mL) 553.5±315.0        637.6± 314.0             0.673
HCV serotype (1/2)          8/2                  9/4             0.377
Biochemical and virological responses
There was no significant difference in RBV concentrations
at wk 4 between the two groups. In the intention-to-treat
analysis as in Table 2, serum ALT levels were within normal
limits in 7 of 10 (70.0%) patients in the NYT group whereas
they were normal in 6 of  13 (46.2%) patients in the control
group at the end of the IFN/RBV treatment (P = 0.253).
At the same time point, HCV-RNA turned negative in 8 of
10 (80.0%) patients in the NYT group whereas it was
negative in 7 of 13 (53.8%) patients in the control group
(P = 0.192). At 6 mo after the NYT/RBV treatment, serum
ALT levels were within normal limits in 8 of  10 (80.0%)
patients in the NYT group while they were within normal
limits in 4 of 13 (30.8%) patients in the control group
(P = 0.489). Sustained virological response (SVR) was
obtained in 4 of 10 (40.0%) patients in the NYT group
whereas it was seen in 4 of 13 (30.8%) in the control group
(P = 0.645). In patients with serotype 1, SVR was obtained
in 3 of 8 (37.5%) patients in the NYT group and 1 of 9
(11.1%) patients in the control group (P = 0.311), whereas
in patients with serotype 2, SVR was recognized in 2 of
2 (100%) in the NYT group and 3 of 4 (75%) in the control
group (P = 0.316).
Table 2  Virological and biochemical results
                  NYT (%)     Control (%) P
Enrolled cases      10              13
Normal ALT  at the end of therapy 7 (70.0)         6 (46.2)          0.253
Negative HCVRNA at the end of therapy 8 (80.0)         7 (53.8)          0.192
Normal ALT 6 mo after therapy 8 (80.0)         4 (30.8)          0.489
Negative HCVRNA 6 mo after therapy 4 (40.0)         4 (30.8)          0.645
Hematological changes
We analyzed the hematological changes in the 18 patients
who received the IFN/RBV treatment for more than 4 wk.
As shown in Table 3 and Figure 2, the maximal decrease of
Hb in the NYT group (2.59±1.10 g/dL) was significantly
(P = 0.026) smaller than that in the control group (3.71±
0.97 g/dL). The minimal Hb during the treatment in the
NYT group (11.66±1.78 g/dL) tended to be higher than
that in the control group (10.10±1.08 g/dL, P = 0.079).
Maximal decrease of erythrocytes in the NYT group
(868 000±474 000/µL) tended to be smaller than that
(1 244 000±419 000/µL) in the control group (P = 0.178).
As shown in Table 1, there were some differences, although
not significant, in age, gender, and body weight, which might
influence the grade of  anemia. We performed a multivariate
analysis using the multiple regression method. Backward
stepwise regression was performed, and a P value greater
than 0.20 was used for a variable removal, and the NYT
administration and serum creatinine were picked up. The
final linear regression model selected only the NYT
administration as a significant variable (P = 0.0042) influencing
maximal hemoglobin decrease (Table 4). There were no
significant differences in the WBC or platelet (Plts) counts
between the two groups.
Table 3  Hematological and immunological results
            NYT                Control               P
max  RBC (×103)         868±474             1.244±419              0.178
max Hb (g/dL)         2.59±1.10               3.71±0.97              0.026
min Hb (g/dL)       11.66±1.78             10.10±1.08              0.079
WBC (wk 24)       3 444±1731             3 204±1143              0.894
Plts (wk 24, ×104)       14.69±5.52             12.77±4.22              0.709
Th1 (wk 4, %)       27.29±11.6             30.20±8.66              0.480
Th2 (wk 4, %)         2.77±1.06               2.30±1.09              0.232
Th1/Th2 (wk 4)       10.89±5.68             15.48±6.87              0.130
GP×[wk 4, nmol/(min mL)]      76.41±31.79             78.96±31.96              0.522
GPx: glutathione peroxidase.
Table 4  Multiple regression analysis
Variable                  Parameter estimate      Standard error  P
Intercept          -1.61742               1.12391              0.1707
NYT administration            1.47645               0.43746              0.0042
Serum creatinine (wk 0)          -3.05400               1.57891              0.0722
Maximal hemoglobin decrease = 1.477 × [NYT administration] -3.054× [serum
creatinine at wk 0]-1.617 (NYT administration: the NYT group, 1; the control
group, 2) Adjusted R square: 0.3923.
Changes in serum erythropoietin concentrations
Serum levels of  erythropoietin were determined in eight
male patients at wk 0 and 4 (four patients from each group),
and there was no significant difference in the increase of
erythropoietin from wk 0 to wk 4 between the two groups
(38.4±21.6 ng/mL in the NYT group vs 45.2±30.3 ng/mL
in the control group, P = 0.885).
Changes in the Th1/Th2 balance
There were no significant changes in Th1, Th2, or the Th1/
Th2 ratio in either group during the observation period in
each group, and there were no significant differences in
these cellular immunological markers between the two groups
at any time point. Table 3 shows the results at wk 4.
Changes in glutathione peroxidase activity
There were no significant changes in glutathione peroxidase
activity during the observation period, and there was no
significant difference in this activity between the two groups
at any time point. Table 3 shows the results at wk 4.
DISCUSSION
In this study, we elucidated, for the first time, the anemia-
ameliorating effect of NYT in the IFN/RBV treatment
for chronic hepatitis C in a randomized controlled trial.
Although NYT possesses a hematopoietic action[10-12], we
speculate that anemia-reducing effect of NYT was derived
from its anti-oxidant[8] and stabilizing actions on the
erythrocytic membrane, ameliorating the hemolytic anemia.
NYT is reported to show an anti-HCV action[7], but NYT
did not affect the anti-viral effect of IFN/RBV therapy in
this study. If we can reduce the grade of anemia and
discontinuation of therapy, it would lead to the increase in
number of patients with SVR.
As mentioned above, NYT is reported to have the
following effects: hematopoietic [10-12], antioxidant [8],
hepatocyte-protective[13], Th1/Th2 balancing[9], and direct
anti-HCV[7]. NYT has been used in the treatment of asthenic
or fatigued patients, especially after operation or severe
infectious diseases[14]. NYT is effective for various signs
and symptoms, including anemia, general malaise, anorexia,
night sweating, sensation of cold in the extremities, cough,
and insomnia[14]. These effects have been analyzed and
verified in the theory of  Traditional Chinese Medicine. From
the viewpoint of hepatitis treatment, these effects of NYT
are suitable for ameliorating the adverse effects of IFN
(general malaise, anorexia, and psychiatric problems) and
that of RBV (anemia). The dose of NYT was 9.0 g/d in
this study, which is a normal dose in Japan.
The precise mechanisms of  RBV-induced anemia are
unknown, but several reports [3,4] suggest that the
accumulation of phosphorylated RBV in erythrocytes due
to the lack of dephosphorylase in erythrocytes impairs the
deformability of  erythrocytes. The accumulated RBV may
affect the antioxidant defense mechanisms of the erythrocytic
membrane. These changes in erythrocytes would lead to
the extravascular destruction of erythrocytes (hemolysis).
Since NYT has an antioxidant action, it may show a beneficial
effect on the erythrocytic membrane. Although NYT would
not affect the accumulated RBV inside the erythrocyte, NYT
might improve erythrocytic deformability in a different
manner, like other herbal medicines with common
components. Therefore, the reasons why NYT ameliorates
RBV-induced anemia might include the protection of
erythrocytic membrane, the improvement of erythrocytic
deformability, and erythropoiesis (Figure 3).
Previous reports showed that erythropoietin[5] and
eicosapentaenoic acid[6] can be effective against RBV-
induced anemia. In the prospective, double-blind, randomized
controlled study by Afdhal et al., in 185 patients [5],
erythropoietin (EPO) was administered after anemia
Figure 2  Effect of Ninjinyoeito on the RBV-induced anemia.
Figure 3  Speculated mechanisms of Ninjinyoeito’s beneficial effect on RBV-
induced anemia.
Table 5  Comparison of NYT and other drugs which were reported to be effective for RBV-induced anemia
Action Mechanisms Indication for anemia in health Form        Adverse reactions         Daily cost
insurance system of Japan               (yen)
NYT Promotion of erythropoiesis, Activation of immature Anemia in Granule        Abdominal discomfort              227.7
protection of erythrocytic erythroid  cells, general,        (frequency unknown)
membrane, improvement of antioxidant effect
erythrocytic deformability
EPA Increase in erythrocyte Increase in EPA content in None Capsule        Jaundice, gynecomastia              353.4
deformability erythrocytic membrane        (frequency unknown),
phospholipids        hemorrhagic tendency,
       liver injury (<0.1%)
EPO Increase in erythropoiesis Stimulation of stem cell Renal anemia Vial for        Thromboembolism,             1 643
differentiation to injection        cerebral hemorrhage,          (750 IU)
erythroid cells        shock (frequency unknown),
       high blood pressure, liver
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The protection of erythrocytic membrane
The improvement of erythrocyte deformability
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developed, and the mean Hb increase was 2.2±1.3 g/dL,
which was significantly greater than 0.1±1.0 g/dL in the
placebo group. However, the use of EPO would be
expensive and would not address the solution of hemolysis.
In the uncontrolled, pilot study by Ide et al., in six patients[6],
eicosapentaenoic acid (EPA) was also administered after
the development of anemia, and the mean Hb significantly
increased from 10.8 to 11.4 g/dL in 1 mo. The effect of
EPA seems to be marginal, and it was tested in a pilot study
and would need a randomized trial. EPA improves
erythrocyte deformability and increases EPA content in
erythrocytic membrane phospholipids[6]. Table 5 summarizes
the comparison among NYT, EPO, and EPA from the
viewpoints of effectiveness, adverse reactions, and cost-
benefits. EPO is expensive, with more adverse effects, but
most effective. NYT is economical, with little adverse reaction.
EPA seems to be intermediate between the above two drugs.
In our study, NYT was administered from the beginning
of IFN/RBV treatment, and we cannot simply compare
the results between the above-mentioned studies and ours.
We would like to test whether NYT improves the RBV-
induced anemia after it occurs, or whether pretreatment
with NYT prevents the anemia.
Erythropoietin response is reported to be subnormal in
the IFN/RBV treatment. Although NYT has a bone
marrow-stimulatory action via enhancing colony stimulating
factors[11], there was no significant difference in the
endogenous erythropoietin response between the NYT and
control groups in our study. Therefore, NYT might
ameliorate RBV-induced anemia, not by stimulating
hematopoiesis, but by reducing hemolysis. We measured
serum glutathione peroxidase activity before and after the
IFN/RBV therapy with or without NYT. There was no
significant change both in time course and between the NYT
and control groups. But, according to the previous reports[8,13]
it is likely that NYT may exert its protective effect on the
erythrocytic membrane by antioxidative action and membrane
stabilization. Serum antioxidant markers other than
glutathione peroxidase might reveal the effect of NYT.
Regarding the combination therapy of IFN and herbal
medicines, Shosaikoto (SST, Shao-chaihu-tang) is prohibited
for use in combination with IFN because this combination
is reported to increase the risk of interstitial pneumonia.
The herbal component Scutellariae radix alone does not
cause interstitial pneumonia, but when used in combination
with other herbal components, some unknown factors causing
interstitial pneumonia are considered to be expressed. NYT
does not contain five of the seven medicinal herbs used in
SST, including Scutellariae radix. Interstitial pneumonia or
any other adverse reactions in relation to NYT use were
not found in this study. Since NYT was used safely in the
IFN/RBV therapy, NYT could be used in combination with
PEG-IFN+RBV for 48 wk, which is considered as the most
effective anti-HCV therapy[2]. This current worldwide standard
was not available during the period of this study in Japan.
In conclusion, NYT ameliorated the RBV-induced anemia
in RCT. NYT did not show any stronger antiviral effect on
HCV, but it was used safely without any adverse reaction in
the combination treatment with IFN/RBV. These results
provide good evidence for the effect of the herbal medicine
NYT. It is suggested that NYT can be used as a supportive
drug for IFN/RBV therapy for chronic hepatitis C. Active
mechanisms are to be elucidated and these results would be
verified in additional studies with more patients.
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